ArticleFrontiers in psychiatry2026
Inaugural year of regulated psilocybin services in Oregon: safety, motivations, and utilization.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Medical and Psychiatric Consultation for Patients Considering State-Regulated Psilocybin Services: A Risk-Reduction Model and Two Illustrative Cases.Research square · 2026Article
- Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026).Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: The Oregon Psilocybin Services (OPS) program is the first statewide, regulated framework for legal psilocybin in the U.S. Analyzing inaugural-year utilization and safety is essential for informing policy and equity monitoring. Methods: We conducted a descriptive analysis of statewide aggregate data from the OPS Public Dashboard (January 1-December 31, 2025). Outcomes included service volume, client demographics, motivations, and acute adverse events. Results: In 2025, 5,935 clients participated in 5,375 sessions. Volume peaked in Q2 (n=1,758) before stabilizing in Q4 (n=1,358). Service tourism was significant, with 32.6% of participants residing outside Oregon. The largest segment was aged 35-49 (~40%); women (57.4%) and LGBTQ+ individuals (27.2%) represented substantial portions of the annual cohort. Racial diversity was limited, with White participants representing 84.1%-91.5% quarterly, while Hispanic/Latino (7.1%) and African American (2.1%) participation lagged. Adverse events were rare, with annual behavioral and medical rates of 2.42 and 2.79 per 1,000 sessions, respectively. Discussion: Full-year data indicate stabilized utilization by a predominantly midlife adult population. While the program successfully reaches sexual and gender minorities, racial disparities persist. High service tourism suggests significant socioeconomic barriers. These findings underscore the program's dual role as a wellness modality and a functional alternative for addressing mental health distress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.